Phase Ii study of spirogermanium in advanced ovarian malignancy
Tropé, C.; Mattsson, W.; Gynning, I.; Johnsson, J.E.; Sigurdsson, K.; Orbert, B.
Cancer Treatment Reports 65(1-2): 119-120
1981
ISSN/ISBN: 0361-5960 PMID: 6261944 Document Number: 171467
In the present phase II trial 18 heavily pretreated patients with advanced ovarian malignancy were treated with spirogermanium, 11 im and seven iv. Objective responses (partial remission) were obtained in two (11%) of the 18 patients, with a remission duration of 5 and 23 + months, respectively. An additional four (22%) patients had stable disease. Each of these six patients had a better quality of life. There were few side effects. Myelosuppression, nausea, or other gastrointestinal side effects did not occur. The present investigation shows that spirogermanium is useful as a palliative chemotherapeutic agent in patients with advanced ovarian malignancy.